Phil Zeitler discusses the pathophysiology of type 2 diabetes in children, and why it is so resistant to conventional management (2:58). 

Read our quick round-up of the GetGoal trials of the daily injectable GLP-1 receptor agonist lixisenatide in people with type 2 diabetes.

Philip Zeitler addresses the possible causes of the rapid trajectory of type 2 diabetes in youth.

“At the time of designing the trial the once-daily administration form was thought to have fewer side effects, although it is now evident that the once weekly administration is well-tolerated,” lead researcher Philip Newsome (University of Birmingham, UK) explained to medwireNews .

Addressing the possible physiological factors that could underlie this disparity, TODAY2 researcher Philip Zeitler (University of Colorado, Aurora, USA) stressed to medwireNews that youths with type 2 diabetes “appear to be hypersecreting, even for whatever degree of insulin sensitivity they have.”

Commenting on the CARMELINA results, Philip Home (Newcastle University, UK) said that the trial “establishes the safety of linagliptin in very high risk people with diabetes in the medium-term.”

The data indicate “that for the first time, a pharmacological therapy might be able to meet treatment goals in type 2 diabetes of both durable glycaemic control and weight loss of a magnitude that will have a considerable impact on clinical outcomes,” say Philip Ambery (MedImmune, Cambridge, UK) and co-authors.

By comparison, just 5% of the 38 patients who received standard medical care achieved this goal, report Philip Schauer (Cleveland Clinic, Ohio, USA) and colleagues.

Sulfonylurea treatment is durably effective with a low rate of side effects in patients with permanent neonatal diabetes caused by mutations in the KCNJ11 gene, a study in The Lancet Diabetes & Endocrinology shows.